Prostate biopsy is an important step that reduces uncertainty and clarifies diagnosis when needed. At ReSurgeClinic in Kyrenia / Cyprus, the biopsy decision is made by evaluating PSA, examination, multiparametric MRI findings, previous results and the patient’s risk profile together. In suitable patients, MRI-targeted fusion biopsy helps sample suspicious areas more consciously.
PSA and MRI togetherTargeted samplingPathology clarityIndividualized decision
During the first consultation
The main complaint, duration of symptoms, previous treatments, accompanying diseases, medications, expectations and relevant examination findings are evaluated together.
Clinical focus
The aim is not to apply the same treatment to every patient, but to understand the underlying mechanism and choose the safest suitable step.
Treatment logic
Follow-up, medical treatment, minimally invasive procedures or surgery are discussed step by step according to the patient’s condition.
What is prostate biopsy?
Prostate biopsy is the process of taking small tissue samples from the prostate for microscopic examination. It is not automatically performed for every PSA elevation, but it is a key diagnostic step in selected patients when cancer suspicion must be clarified.
The aim is not only to make a diagnosis, but to avoid unnecessary procedures while providing clarity without delay when needed.
What does MRI fusion biopsy target?
When a suspicious area is detected on multiparametric MRI, targeting that area during biopsy may make the diagnostic process more meaningful. MRI-targeted biopsy may be combined with systematic sampling.
Targeted biopsy is not mandatory for every patient, but in selected patients with MRI findings it helps plan where samples should be taken more consciously.
How should preparation be done?
Blood thinners, infection risk, allergy history, previous biopsy or prostate infection are assessed before the procedure.
The patient should be informed beforehand about expected findings after the procedure, warning signs requiring quick contact and how pathology results will be interpreted.
How is the decision made after the result?
Pathology is not evaluated only as “cancer present/absent”. Tumor grade, extent, PSA, MRI and the patient’s general condition are interpreted together.
Follow-up may be enough for some patients, while active surveillance, surgery or radiotherapy may be discussed for others.
PSA / examination
Biopsy decision is based on the clinical picture and risk assessment, not a single PSA value.
MRI targeting
If suspicious MRI areas exist, targeted sampling can be planned.
Safe preparation
Blood thinners, infection risk and post-procedure warning signs should be clarified.
Decision with pathology
The next step is determined by pathology, risk classification and patient characteristics.
Frequently asked questions
Can definitive diagnosis be made without biopsy?
In many cases tissue diagnosis is required. MRI and PSA may increase suspicion, but pathology clarifies the decision.
Does everyone need MRI fusion biopsy?
No. The decision is based on MRI findings, PSA, examination and clinical risk.
What should be considered after biopsy?
Temporary changes in urine or semen color may occur. Fever, severe pain or inability to urinate require prompt evaluation.
